SCHEMBL2382224

SCHEMBL2382224

COC(=O)CNC(=O)c1c(O)c2cccc(OC)c2n(C)c1=O

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 10/20 0.53
TSHR P16473 1/20 0.53
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KDM4E B2RXH2 1/20 0.47
EGFR P00533 1/20 0.47
SRC P12931 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
CYP19A1 P11511 1/20 0.46
NQO2 P16083 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2383861 0.91 HIF1A (0.64) HIF1A
SCHEMBL12254449 0.91 HIF1A (0.53) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL2382489 0.83 HDAC4 (0.54) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL2383323 0.83 CYP19A1 (0.52) HIF1ATSHRMEN1KMT2AKDM4E
SCHEMBL2384134 0.82 KMT2A (0.70) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL15419065 0.82 EGFR (0.47) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL10676787 0.81 EGFR (0.70) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL2384819 0.80 L3MBTL1 (0.49) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL2384824 0.80 L3MBTL1 (0.49) HIF1ATSHRMEN1KMT2ANPC1
SCHEMBL2383867 0.80 L3MBTL1 (0.47) HIF1ATSHRMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP claimed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US claimed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 HIF1A 4/4885TSHR 4604/4885MEN1 3474/4885
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 HIF1A 4/4885TSHR 4541/4885MEN1 3364/4885
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof EGLN3, HIF1AN, EGLN2 HIF1A 4/4885TSHR 4541/4885MEN1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.